Clinical trial risk in chronic obstructive pulmonary disease: the effects of drug class and inclusion criteria

chest x-ray
Friday, December 9, 2016 - 7:54am

Congratulations to MBiotech student Demetri Anastasopulos and MBiotech alum Jeffrey Tam who, under the supervision of Prof. Jayson Parker, recently published their article “Clinical trial risk in chronic obstructive pulmonary disease: the effects of drug class and inclusion criteria” in Respiration. Their study examined the risk of clinical trial failure in testing new drugs for chronic obstructive pulmonary disease. They found that approximately 87% of all drugs entering clinical testing failed, while combined drug regimens had a better success rate. Certain drug classes, such as muscarinic antagonists, had much better success rates. Their study provides insight into how pulmonary disease can be treated more effectively in future. Demetri is presently in an internship as a commercial effectiveness associate at Purdue Pharma and Jeffrey Tam in pharma sales for GlaxoSmithKline as a respiratory specialist.

Congratulations on this important study!